Teva jumps ahead of Q3 results

The Israeli pharmaceutical firm, managed by CEO Richard Francis, will publish its third quarter monetary outcomes on Wednesday. Based on Yahoo Finance, analysts count on income to be just like the corresponding quarter of 2024 – $4.33 billion, and non-GAAP earnings per share of $0.67, down $0.02 from the corresponding quarter.

Based on the Wall Avenue Journal, out of 10 analysts protecting Teva inventory, 9 are constructive and one is damaging, and the typical value goal is $25.57 – a, 24.9% premium on the present share value. Final week, Jefferies analyst Dennis Ding printed a evaluation forward of Teva’s report and addressed the problem of the IRA laws designed to decrease drug costs within the US, amongst different issues, within the pharmaceutical sector. Ding notes that buyers will deal with what Teva administration mentioned concerning the impression on the drug Austedo (a branded drug for motion issues) and estimates that the corporate’s forecast for $2.5 billion in Austedo gross sales in 2027 will probably not change. This ieven although the value of the drug is predicted to fall.

Ding offers a “Purchase” suggestion for Teva’s inventory with a value goal of $24, a premium of 17.2%. On the identical time, Teva introduced that it has received an Excellence Award on the Economist Group’s EuroFinance Treasury convention, for the corporate’s money optimization and dealing capital administration.

Revealed by Globes, Israel enterprise information – en.globes.co.il – on November 3, 2025.

© Copyright of Globes Writer Itonut (1983) Ltd., 2025.